ArticleDiscover oncology2026
A long-term survival prediction model for non-small cell lung cancer based on blood inflammatory biomarkers.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung cancer with the highest incidence and mortality rates of malignant tumors in the world, has become one of the greatest economic burden diseases in China. To construct a simple, efficient, and practical prognostic model for lung cancer can accurately guide the development of treatment plans for patients without additional expenses, which is beneficial for reducing medical costs and improving patients’ quality of life.
methodsClinical characteristics and blood inflammatory biomarkers (BIBs) of 501 patients diagnosed with NSCLC for the first time between June 2004 and December 2016 were collected. Group analyses were conducted on clinical characteristics and BIBs. Relevant factors for overall survival were selected using LASSO regression, and a prognostic model based on BIBs was established.
resultsKaplan–Meier analysis indicated statistically significant differences in lung cancer survival among subgroups of gender, smoking, pathological type, TNM stage, surgical status, and Performance Status (PS) score (all P < 0.05), whereas no significant differences were observed among age and Charlson Comorbidity Index (CCI) subgroups (all P > 0.05). Statistically significant differences in lung cancer survival were also observed among subgroups of various BIBs (all P < 0.05). The BIBs prognostic model demonstrated good predictive value with AUCs of 0.811, 0.891, 0.856, and 0.841 for 1-year, 3-year, 5-year, and 10-year survival, respectively, effectively predicting NSCLC prognosis.
conclusionThe prognostic model based on clinical characteristics and BIBs exhibit simplicity, efficiency, and broad application prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.